+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
course on usfda regulation
27 Oct 2014

New molecule approved by USFDA tilldate in 2014

2014 New Molecule Approved tilldate
No. Drug Name Active Ingredient Date What It’s Used For
34 Esbriet pirfenidone 15-10-2014 For the treatment of idiopathic pulmonary fibrosis (IPF)
33 Ofev nintedanib 15-10-2014 For the treatment of idiopathic pulmonary fibrosis (IPF)
32 Lumason sulfur hexafluoride lipid microsphere 10-10-2014 For patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound waves
31 Akynzeo netupitant and palonosetron 10-10-2014 To treat nausea and vomiting in patients undergoing cancer chemotherapy
30 Harvoni ledipasvir/sofosbuvir 10-10-2014 To treat chronic hepatitis C virus (HCV) genotype 1 infection
29 Trulicity dulaglutide 18-09-2014 To treat adults with type 2 diabetes.
28 Movantik naloxegol 16-09-2014 To treat opioid-induced constipation in adults with chronic non-cancer pain.
27 Keytruda pembrolizumab 04-09-2014 For treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.
26 Cerdelga eliglustat 19-08-2014 For the long-term treatment of adult patients with the Type 1 form of Gaucher disease
25 Plegridy peginterferon beta-1a 15-08-2014 For the treatment of patients with relapsing forms of multiple sclerosis
24 Belsomra suvorexant 13-08-2014 To treat difficulty in falling and staying asleep (insomnia)
23 Orbactiv oritavancin 06-08-2014 To treat adults with skin infections
22 Jardiance empagliflozin 01-08-2104 To improve gylcemic control in adults with type 2 diabetes
21 Striverdi Respimat olodaterol 31-07-2014 To treat chronic obstructive pulmonary disease
20 Zydelig idelalisib 23-07-2014 To treat patients with trhee types of blood cancers
19 Kerydin tavaborole 07-07-2014 For the topical treatment of onychomycosis of the toenails
18 Beleodaq belinostat 03-07-2014 To treat patients with peripheral T-cell lymphoma (PTCL)
17 Sivextro (tablet) tedizolid phosphate 20-06-2014 To treat adults with skin infections
16 Jublia efinaconazole 06-06-2014 Treat mild to moderate onychomycosis (fungal infection)
15 Dalvance dalbavancin 23-05-2014 To treat adults with skin infections
14 Entyvio vedolizumab 20-05-2014 To treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s disease
13 Zontivity vorapaxar 08-05-2014 To reduce the risk of heart attacks and stroke in high-risk patients
12 Zykadia ceritinib 29-04-2014 To treat patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC)
11 Sylvant siltuximab 23-04-2014 To treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes)
10 Cyramza ramucirumab 21-04-2014 To treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma
9  Tanzeum albiglutide 15-04-2014 To improve glycemic control, along with diet and exercise, in adults with type 2 diabetes
8 Otezla apremilast 21-03-2014 To treat adults with active psoriatic arthritis (PsA)
7 Impavido miltefosine 19-03-2014 To treat a tropical disease called leishmaniasis
6 Neuraceq florbetaben F 18 injection 19-03-2014 For Positron EmissionTomography (PET) imaging of the brain
5 Myalept metreleptin for injection 24-02-2014 To treat the complications of leptin deficiency
4 Northera droxidopa 18-02-2014 To treat neurogenic orthostatic hypotension (NOH)
3 Vimizim elosulfase alfa 14-02-2014 Treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome)
2 Hetlioz tasimelteon 31-01-2014 To treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep.
1 Farxiga dapaglifozin 08-01-2014 To improve glycemic control, along with diet and exercise, in adults with type 2 diabetes

Reference: USFDA official notification

 

Drug Regulatory Affairs Course

Pharmaceutical Regulatory Affairs courses are conceptualized with vision to create effective Regulatory Affairs Manager for Pharma Industry. This course gives practical knowledge of the functionalities of Regulatory Manager with practical exposure.

View

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.